Carcinosinum for Autism Spectrum Disorder(ECASD)

Efficacy of Carcinosinum versus Individualized Homoeopathic Medicines in the Management of Social Deficits in Autism Spectrum Disorder- A Double-Blind Randomized Controlled Trial - ECASD (Efficacy of Carcinosinum in Autism Spectrum Disorder).

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/10/058402

Enrollment

122

Registered

2023-10-06

Start date

Unknown

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F840- Autistic disorder

Interventions

Intervention1: Carcinosinum 30C/200C/1M single dose orally followed up every month according to principles of posology in homoeopathy: Homeopathic, Nosode remedy Control Intervention1: Individualized

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children aged 3-16 years of both genders 2. Fulfilling criteria for DSM V criteria for Autism Spectrum Disorder (299.00)

Exclusion criteria

Exclusion criteria: 1. Children receiving conventional or other systems of medicine either for Autism or comorbid physical or psychiatric conditions 2. Severe to profound intellectual disability 3. If Parents/caregivers are unwilling to give informed consent.

Design outcomes

Primary

Measure	Time frame
change in Stanford Social Dimensions Scale (SSDS)Timepoint: Baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks	—

Secondary

Measure	Time frame
Indian Scale for Assessment of Autism (ISSA) Timepoint: 50% Change in symptoms in 1 year	—

Countries

India

Contacts

Public ContactDr Deepthi Gilla

National Homoeopathy Research Institute in Mental Health, (NHRIMH) Kottayam.

drdeepthigilla@gmail.com8111990221

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026